Liver metastases represent one of the most challenging settings in melanoma, with significantly poorer responses to immunotherapy compared to other sites of disease. Our project investigates how the unique immune and metabolic microenvironment of the liver shapes tumour behaviour, promotes resistance, and drives systemic immune suppression. By integrating patient data with advanced preclinical models, we are uncovering mechanisms such as hypoxia, angiogenesis, and metabolic reprogramming that exclude T cells from tumours. The ultimate goal is to identify therapeutic strategies that overcome liver-specific resistance and improve outcomes for these high-risk patients.